We are pleased to announce that two new treatments have been recently approved by the FDA for the treatment of atopic dermatitis. Oregon Medical Research Center and our patients contributed to the approval by enrolling in the pivotal studies that provided the data showing the benefits of the treatment options. We want to thank all of our patient volunteers who helped make this treatment available.
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis